Category: BioTech

FB Nasdaq FB Facebook
BioTech

Biotech Active Runners: Novavax (NASDAQ:NVAX), VIVUS (NASDAQ:VVUS), Rexahn Pharmaceuticals (NYSEMKT:RNN), Ariad Pharmaceuticals (NASDAQ:ARIA)

Novavax, Inc. (NASDAQ:NVAX), announced on Thursday that the Biomedical Advanced Research and Development authority extended the base period of performance of a contract with the pharmaceutical company for its recombinant seasonal and pandemic influenza vaccines. Novavax, Inc. (NASDAQ:NVAX) stock performance was 1.27% in last session and finished the day at $6.38. Traded volume was 13,436,282 million shares in the last session and the average volume … Continue reading Biotech Active Runners: Novavax (NASDAQ:NVAX), VIVUS (NASDAQ:VVUS), Rexahn Pharmaceuticals (NYSEMKT:RNN), Ariad Pharmaceuticals (NASDAQ:ARIA)

Colin Pettis
BioTech

Biotech Losers In News: Agios Pharmaceuticals (NASDAQ:AGIO), Cell Therapeutics (NASDAQ:CTIC), NewLink Genetics (NASDAQ:NLNK), Mirati Therapeutics (NASDAQ:MRTX)

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) present at the Cowen and Company 34th Annual Health Care Conference at the Boston Marriott Copley Place. Agios Pharmaceuticals Inc (NASDAQ:AGIO) stock performance was -5.69% in last session and finished the day at $29.48. Traded volume was 263,884 million shares in the last session and the average volume of the stock remained 254.15 million shares. Agios Pharmaceuticals Inc (NASDAQ:AGIO) insider ownership … Continue reading Biotech Losers In News: Agios Pharmaceuticals (NASDAQ:AGIO), Cell Therapeutics (NASDAQ:CTIC), NewLink Genetics (NASDAQ:NLNK), Mirati Therapeutics (NASDAQ:MRTX)

Jayne Crisman
BioTech

Biotech Gainers In News: Inovio Pharmaceuticals (NYSEMKT:INO), Dendreon Corporation (NASDAQ:DNDN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Dyax (NASDAQ:DYAX)

Inovio Pharmaceuticals Inc (NYSEMKT:INO) on Feb. 27 announced the pricing of an underwritten public offering of 18,966,000 shares of common stock for a public offering price of $2.90 per share. The gross proceeds to Inovio from this offering are expected to be approximately $55 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company. Inovio Pharmaceuticals Inc (NYSEMKT:INO) … Continue reading Biotech Gainers In News: Inovio Pharmaceuticals (NYSEMKT:INO), Dendreon Corporation (NASDAQ:DNDN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Dyax (NASDAQ:DYAX)

Colin Pettis
BioTech

Biotech Runners: VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

VIVUS Inc. (NASDAQ:VVUS) stock was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating. They now have a $8.00 price target on the stock, down previously from $15.00. VIVUS, Inc. (NASDAQ:VVUS) stock performance was 1.00% in last session and finished the day at $6.09. Traded volume was 5,364,675 million shares in the last session and the average volume … Continue reading Biotech Runners: VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

Mark DeFrance
BioTech, business

Stocks Bounding Upward on Monday: FTD (NASDAQ:FTD), Highpower International (NASDAQ:HPJ), Tesla (NASDAQ:TSLA)

FTD (NASDAQ:FTD) gains nearly 5% Monday, subject of a largely favorable Barron’s weekly article ahead of the online florist’s earnings report this week. FTD was spun off from United Online in November and its shares have barely moved since. Barron’s thinks Wall Street is overlooking the company’s solid balance sheet, with net debt of $191 million, or 25% of total capitalization.   Barron’s says FTD could … Continue reading Stocks Bounding Upward on Monday: FTD (NASDAQ:FTD), Highpower International (NASDAQ:HPJ), Tesla (NASDAQ:TSLA)

John Meady
BioTech

Medical Stocks in the News: Celldex Therapeutics (NASDAQ:CLDX), NeuroMetrix (NASDAQ:NURO)

Celldex Therapeutics (NASDAQ:CLDX) is lower Monday afternoon after its net loss  widened and revenue declined compared to the year-ago period. Results were better than Wall Street’s expectations but could not fend off sellers. In early afternoon action, shares of the biopharmaceutical company are down 11% at $26.15 and traded earlier as low as $25.76. The stock moves within a 52-week range of $9.13 – $38.84. Celldex … Continue reading Medical Stocks in the News: Celldex Therapeutics (NASDAQ:CLDX), NeuroMetrix (NASDAQ:NURO)

Kevin Long